Opko Health issues $125M notes secured by Mazdutide royalties

Opko Health Issues $125M Notes Secured by Mazdutide Royalties

Opko Health, Inc. (NASDAQ: OPK) has issued $125 million in secured notes backed by royalties from Eli Lilly’s Mazdutide, a GLP-1-based obesity drug commercialized in China by Innovent Biologics. The transaction is part of the company’s broader strategy to leverage its intellectual property and partnership agreements to secure funding for ongoing research and development initiatives.

The Mazdutide royalties, which began in the fourth quarter of 2025, are derived from Eli Lilly’s commercialization of the drug in China. In the fourth quarter of 2025, Opko recorded $4.3 million in royalty revenue from Mazdutide sales, reflecting the drug’s commercial success in the region. The $125 million in secured notes provides Opko with additional liquidity while allowing it to retain future royalty income from the drug.

This move aligns with Opko’s focus on capital efficiency and strategic partnerships. The company has been actively repurchasing shares and restructuring its balance sheet, with $113 million in remaining buyback authorization as of December 31, 2025. The Mazdutide-backed notes offer a non-dilutive funding source, enabling Opko to continue investing in its pipeline of therapeutics and diagnostics without issuing additional equity.

The issuance of the notes also reflects the growing importance of Mazdutide in Opko’s revenue mix. The drug’s commercialization in China has contributed to a steady increase in royalty income, with Opko expecting continued growth as Innovent Biologics expands its market reach. The notes are structured to provide Opko with a stable cash flow stream tied to the performance of Mazdutide, which has demonstrated strong demand in the Chinese market.

Opko’s CFO, Adam Logal, emphasized the company’s commitment to capital allocation and shareholder returns during the fourth-quarter 2025 earnings call. “We have approximately $113 million remaining under our buyback authorization and expect to accelerate our repurchase program over the short term,” Logal stated. The Mazdutide-backed notes are expected to support these efforts by providing additional flexibility in managing the company’s capital structure.

The notes issuance is part of a broader trend in the biopharmaceutical industry, where companies increasingly use revenue-sharing and royalty-based financing to fund development programs. For Opko, this approach allows it to maintain financial stability while advancing its pipeline of immuno-oncology and infectious disease therapies, including programs in collaboration with Regeneron and Merck.

Looking ahead, Opko has outlined financial guidance for 2026, with total revenue expected to range between $530 million and $560 million. The company anticipates continued growth in its pharmaceutical segment, driven by product sales, profit-sharing agreements, and royalty income from partnerships like the Mazdutide deal. The secured notes are expected to play a role in supporting these objectives by providing a reliable source of capital for R&D and operational expenses.

In summary, Opko Health’s issuance of $125 million in notes secured by Mazdutide royalties represents a strategic financial move that enhances liquidity while preserving future revenue potential. The transaction underscores the company’s ability to monetize its partnerships and intellectual property in a capital-efficient manner, supporting its long-term growth and innovation goals.